We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
Cap. Flow
+$103M
Cap. Flow %
29.91%
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$17.6M
2
AMRN icon
Amarin Corp
AMRN
+$14.4M
3
DHR icon
Danaher
DHR
+$12.8M
4
EHTH icon
eHealth
EHTH
+$11.1M
5
GSK icon
GSK
GSK
+$10.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$5.19M
2
MRK icon
Merck
MRK
+$3.53M
3
ZGNX
Zogenix, Inc.
ZGNX
+$3.24M
4
TSRO
TESARO, Inc.
TSRO
+$2.67M
5
ABT icon
Abbott
ABT
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 86.25%
2 Industrials 8.36%
3 Financials 3.65%
4 Miscellaneous 1.46%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMRN icon
1
Amarin Corp
AMRN
$238M
$42.8M 12.48%
103,014
+39,844
+63% +$14.4M
2018 Q1
4 quarters
GSK icon
2
GSK
GSK
$99.3B
$34.1M 9.94%
642,548
+218,961
+52% +$10.9M
2018 Q1
4 quarters
RCM icon
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$28.7M 8.36%
2,963,659
+614,353
+26% +$5.56M
2017 Q4
5 quarters
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$27.3M 7.95%
495,429
-68,000
-12% -$3.24M
2017 Q4
5 quarters
DHR icon
5
Danaher
DHR
$161B
$21M 6.12%
179,086
+125,163
+232% +$12.8M
2018 Q3
2 quarters
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
$18.8M 5.48%
+330,601
New +$17.6M
2019 Q1
0 quarters
SNY icon
7
Sanofi
SNY
$96.3B
$14.7M 4.29%
332,402
+26,160
+9% +$1.12M
2017 Q4
5 quarters
RDUS icon
8
DELISTED
Radius Health, Inc.
RDUS
$12.9M 3.75%
645,417
+93,364
+17% +$1.7M
2017 Q4
5 quarters
EHTH icon
9
eHealth
EHTH
$18.6M
$12.5M 3.65%
+200,649
New +$11.1M
2019 Q1
0 quarters
ASND icon
10
Ascendis Pharma A/S
ASND
$14.8B
$12.2M 3.55%
103,296
+88,042
+577% +$7.71M
2017 Q4
5 quarters
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.82B
$9.96M 2.91%
83,574
+43,080
+106% +$5.54M
2018 Q2
3 quarters
ENSG icon
12
The Ensign Group
ENSG
$10.3B
$8.17M 2.38%
170,554
+79,074
+86% +$3.46M
2017 Q4
5 quarters
ABMD
13
DELISTED
Abiomed Inc
ABMD
$7.81M 2.28%
27,339
+13,400
+96% +$4.45M
2017 Q4
5 quarters
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$127B
$7.03M 2.05%
38,229
+1,737
+5% +$321K
2017 Q4
5 quarters
FATE icon
15
Fate Therapeutics
FATE
$218M
$6.15M 1.79%
350,011
+185,011
+112% +$2.92M
2018 Q4
1 quarter
TGTX icon
16
TG Therapeutics
TGTX
$8.31B
$6.02M 1.76%
748,594
+683,594
+1,052% +$3.69M
2018 Q1
4 quarters
DCPH icon
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.81M 1.7%
250,432
+180,732
+259% +$4.73M
2018 Q4
1 quarter
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
$5.45M 1.59%
114,779
-118,011
-51% -$5.19M
2017 Q4
5 quarters
ARRY icon
19
DELISTED
Array Biopharma Inc
ARRY
$5.22M 1.52%
214,112
+123,700
+137% +$2.58M
2017 Q4
5 quarters
ARGX icon
20
argenx
ARGX
$51.5B
$4.91M 1.43%
39,334
+1,110
+3% +$130K
2017 Q4
5 quarters
ICPT
21
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.9M 1.43%
+43,800
New +$4.79M
2019 Q1
0 quarters
PTCT icon
22
PTC Therapeutics
PTCT
$4.96B
$3.79M 1.1%
+100,600
New +$3.38M
2019 Q1
0 quarters
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.39M 0.99%
75,721
-5,650
-7% -$259K
2018 Q1
4 quarters
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$1.99B
$3.36M 0.98%
412,876
+248,917
+152% +$2.13M
2017 Q4
5 quarters
ARQL
25
DELISTED
Arqule Inc
ARQL
$3.1M 0.9%
646,918
+302,300
+88% +$1.17M
2018 Q2
3 quarters
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.

  • Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
  • Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
  • Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
  • Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
  • Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
  • Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
  • Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.